Modified CpG oligodeoxynucleotide with improved immunoregulatory function
AssigneeYonsei University
InventorsSoo Kie Kim, Seung Kyu Park, Su Jung Park, Hyun Chul Cho
Life of this patent
Estimating the term…
Loading patent…
AssigneeYonsei University
InventorsSoo Kie Kim, Seung Kyu Park, Su Jung Park, Hyun Chul Cho
Estimating the term…
The present invention relates to a modified CpG oligodeoxynucleotide (ODN) which is prepared by coupling a consecutive sequence of deoxyribothymine (dT) to the 3′-terminus of CpG ODN having immunoregularory function, thereby improving immunoactivity of splenocytes, macrophages and peripheral mononuclear cells, and therefore, can be effectively used as a vaccine adjuvant for preventing and treating hepatitis B or an anti-cancer agent. Since the phosphorothioate CpG ODN having the consecutive sequence of dT at its 3′-terminus shows high activity inducing Th-1 immune response and does not elicit in vivo toxicity with guaranteeing its safety, it can be effectively used as a vaccine adjuvant.
A structurally modified oligodeoxynucleotide (ODN) consisting of the nucleotide sequence of SEQ ID NO:
A structurally modified oligodeoxynucleotide (ODN) comprising the nucleotide sequence of SEQ ID NO:
Dependencies are inferred from the claim text.